PROTACs is a novel technique in protein drug research field. Unlike traditional protein inhibitors, PROTACs are potential to target undruggable protein. Therefore, it has become a potential cancer therapy strategy. PROTACs appearsRead More…
Protacs: STAT3 specific small molecule degradant inhibits tumor growth
Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family, which responds to a variety of cytokines, growth factors and other signals and activates the expression ofRead More…
The First PROTAC Drug ARV-110’s Latest Clinical Data: Preliminary Display of Anti-tumor Activity
Among the drugs developed in Arvinas, ARV-110 is the first oral PRAOTC small molecule drug to enter clinical trials in the field of proteolytic targeted chimerism, selectively targeting the degradation of androgenRead More…